ATE359780T1 - Promotoren für die expression des myelin assoziierten glycoproteins (mag) - Google Patents

Promotoren für die expression des myelin assoziierten glycoproteins (mag)

Info

Publication number
ATE359780T1
ATE359780T1 AT00931568T AT00931568T ATE359780T1 AT E359780 T1 ATE359780 T1 AT E359780T1 AT 00931568 T AT00931568 T AT 00931568T AT 00931568 T AT00931568 T AT 00931568T AT E359780 T1 ATE359780 T1 AT E359780T1
Authority
AT
Austria
Prior art keywords
mag
promotors
myelin
expression
associated glycoprotein
Prior art date
Application number
AT00931568T
Other languages
English (en)
Inventor
Masakazu Kawasaki
Nobuharu Gotoh
Yoshiharu Hayashi
Kazuyuki Kawasaki
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Application granted granted Critical
Publication of ATE359780T1 publication Critical patent/ATE359780T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00931568T 1999-05-25 2000-05-25 Promotoren für die expression des myelin assoziierten glycoproteins (mag) ATE359780T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14433699 1999-05-25

Publications (1)

Publication Number Publication Date
ATE359780T1 true ATE359780T1 (de) 2007-05-15

Family

ID=15359751

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00931568T ATE359780T1 (de) 1999-05-25 2000-05-25 Promotoren für die expression des myelin assoziierten glycoproteins (mag)

Country Status (21)

Country Link
US (2) US7166630B2 (de)
EP (1) EP1186296B1 (de)
KR (1) KR100660955B1 (de)
CN (1) CN1160072C (de)
AT (1) ATE359780T1 (de)
AU (1) AU774471B2 (de)
BG (1) BG106254A (de)
BR (1) BR0011551A (de)
CA (1) CA2373967A1 (de)
CZ (1) CZ20014203A3 (de)
DE (1) DE60034448D1 (de)
EE (1) EE200100621A (de)
HK (1) HK1044721A1 (de)
HU (1) HUP0201485A3 (de)
IL (1) IL146726A0 (de)
IS (1) IS6173A (de)
MX (1) MXPA01012188A (de)
NO (1) NO20015733L (de)
NZ (1) NZ516261A (de)
RU (1) RU2241454C2 (de)
WO (1) WO2000071119A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1354664B1 (de) 2002-04-20 2010-11-17 Haas Laser GmbH & Co. KG Einrichtung zur Überwachung eines optischen Elements eines Bearbeitungskopfes einer Maschine zur thermischen Bearbeitung eines Werkstücks

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19541146A1 (de) 1995-10-25 1997-04-30 Schering Ag Imidazolderivate und deren Verwendung als Stickstoffmonoxid-Synthase-Inhibitoren
CN1092645C (zh) * 1995-12-27 2002-10-16 卫福有限公司 糖尿病并发症的预防/治疗药

Also Published As

Publication number Publication date
NZ516261A (en) 2003-11-28
CN1356900A (zh) 2002-07-03
NO20015733D0 (no) 2001-11-23
IL146726A0 (en) 2002-07-25
US20060270712A1 (en) 2006-11-30
NO20015733L (no) 2002-01-11
EP1186296A4 (de) 2004-12-22
AU774471B2 (en) 2004-07-01
US20050090531A1 (en) 2005-04-28
IS6173A (is) 2001-11-23
EP1186296A1 (de) 2002-03-13
CZ20014203A3 (cs) 2002-06-12
CN1160072C (zh) 2004-08-04
DE60034448D1 (de) 2007-05-31
HUP0201485A3 (en) 2004-01-28
KR100660955B1 (ko) 2006-12-26
EP1186296B1 (de) 2007-04-18
RU2241454C2 (ru) 2004-12-10
MXPA01012188A (es) 2003-06-30
KR20020015332A (ko) 2002-02-27
HK1044721A1 (zh) 2002-11-01
AU4949700A (en) 2000-12-12
BG106254A (en) 2002-08-30
EE200100621A (et) 2003-02-17
CA2373967A1 (en) 2000-11-30
WO2000071119A1 (fr) 2000-11-30
BR0011551A (pt) 2002-04-02
US7166630B2 (en) 2007-01-23
HUP0201485A2 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
NO2022019I1 (no) Eribulin eller et farmasøytisk akseptabelt salt derav - forlenget SPC
DE69012840T2 (de) Adenosin-Derivate, die eine Aktivität gegen Bluthochdruck haben.
ES2172585T3 (es) Derivado de benzoimidazol.
EP1197210A4 (de) Mittel zur verhinderung der chronischen abstossreaktion infolge einer organtransplantation
UA83691C2 (ru) Применение замещенных 2-аминотетралинов для упреждающего лечения болезни паркинсона
PT916651E (pt) DERIVADOS DE áCIDO FENILALQUILCARBOXILICO
EP0285278A3 (en) Method of treating anxiety with tetrahydrobenzûc,d¨indole-6-carboxamides
ATE359780T1 (de) Promotoren für die expression des myelin assoziierten glycoproteins (mag)
NO990672L (no) Neuraminsyreforbindelser
NO20070421L (no) Radiosensitiviserende middel
SE9704770D0 (sv) New use
FR2835253B1 (fr) Composes, en particulier de derives urees ou esters de l'acide haloacetamidobenzoique et leur utilisation pour le traitement de maladies parasitaires
DE69729890D1 (de) Heilmittel/vorbeugemittel für erkrankungen der atemwege
NO20013464L (no) Anvendelse av 3-isoksazolidinoner og hydroksylaminsyrer for behandling av infeksjoner
TH65539A (th) การป้องกันการแตกของพลาคด้วยสารยับยั้ง acat
DE69407227D1 (de) Die Verwendung von 2-Phenylmethylene-1-3'-(amino)-2-(hydroxy)-propoxy-imino-cyclohexane-Derivaten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties